Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHB4 | P54760 | 3/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
| ▸ | NAMPT | P43490 | 2/20 | 0.37 |
| ▸ | ELANE | P08246 | 1/20 | 0.36 |
| ▸ | CPT2 | P23786 | 1/20 | 0.36 |
| ▸ | CPT1A | P50416 | 1/20 | 0.36 |
| ▸ | CPT1B | Q92523 | 1/20 | 0.36 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.36 |
| ▸ | CTSK | P43235 | 4/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | ASAH1 | Q13510 | 2/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776305 | 0.94 | ASAH1 (0.41) | CHRM4NAMPTITGB3ITGA2BCTSK | |
| SCHEMBL16776303 | 0.92 | ASAH1 (0.44) | NAMPTITGB3ITGA2BKMOASAH1 | |
| SCHEMBL16776370 | 0.92 | EPHX1 (0.40) | EPHB4CHRM4NAMPTITGB3ITGA2B | |
| SCHEMBL16776316 | 0.90 | CA12 (0.42) | CHRM4NAMPTKMOASAH1TRPV1 | |
| SCHEMBL16776369 | 0.88 | CTSK (0.41) | CHRM4NAMPTCTSKKCNH2KMO | |
| SCHEMBL16776320 | 0.87 | KMT2A (0.43) | EPHB4CHRM4GRIN1GRIN2BTRPV1 | |
| SCHEMBL16776331 | 0.85 | CYP1A2 (0.43) | NAMPT | |
| SCHEMBL16776302 | 0.84 | POLB (0.43) | EPHB4KMO | |
| SCHEMBL16776325 | 0.84 | CHRM4 (0.40) | CHRM4NAMPTCTSKKCNH2KMO | |
| SCHEMBL16776356 | 0.83 | CYP1A2 (0.38) | NAMPTKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | EPHB4 4864/4885CHRM4 4421/4885NAMPT 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.